EI
AERI

EAM Investors’s Aerie Pharmaceuticals AERI Stock Holding History

EAM Investors’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-40,782
Closed -$2.44M – 385
2017
Q4 		$2.44M Sell
40,782
-26,886
-40% -$1.63M 0.44% 93
2017
Q3 		$3.29M Sell
67,668
-5,262
-7% -$287K 0.44% 59
2017
Q2 		$3.83M Sell
72,930
-20,033
-22% -$933K 0.63% 29
2017
Q1 		$4.22M Sell
92,963
-7,796
-8% -$348K 0.66% 16
2016
Q4 		$3.81M Sell
100,759
-24,173
-19% -$914K 0.51% 35
2016
Q3 		$4.71M Buy
+124,932
New +$2.76M 0.63% 14
2015
Q2 		– Sell
-115,038
Closed -$3.6M – 389
2015
Q1 		$3.6M Sell
115,038
-14,778
-11% -$428K 0.42% 68
2014
Q4 		$3.79M Buy
129,816
+37,327
+40% +$947K 0.53% 37
2014
Q3 		$1.91M Buy
92,489
+62,759
+211% +$1.24M 0.39% 77
2014
Q2 		$736K Buy
+29,730
New +$515K 0.14% 312

Other funds holding AERI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

EAM Investors's AERI Position: Q1 2018 in Review

EAM Investors sold out of Aerie Pharmaceuticals (AERI) in Q1 2018, closing a stake of 40,782 shares — an estimated $2.44M sold.

EAM Investors first reported a position in AERI in Q2 2014 and held it in 10 quarters. The position peaked at $4.71M in Q3 2016. 172 funds tracked by Wall St. Rank hold AERI as of Q1 2018.

  • EAM Investors reported no remaining Aerie Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • EAM Investors sold 40,782 Aerie Pharmaceuticals shares in Q1 2018, an estimated $2.44M.
  • EAM Investors first reported a position in Aerie Pharmaceuticals in Q2 2014 and held it in 10 quarters.
  • EAM Investors's Aerie Pharmaceuticals position peaked at $4.71M in Q3 2016.
  • 172 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q1 2018.

Based on EAM Investors's 13F filing for Q1 2018, filed 14 May 2018.